>欧洲内容许可市场的电子临床结果评估 (eCOA)，按产品（本地解决方案、基于云的解决方案、基于 Web 的解决方案）、方法（临床报告结果评估 (ClinRO)、患者报告结果评估 (PRO)、观察者报告结果评估 (ObsRO)、绩效结果评估 (PerfO)）、最终用户（商业服务提供商、医院和移植中心、研究实验室、学术机构）、平台（合同研究组织、制药和生物制药公司、医疗器械制造商、医院和临床实验室、咨询服务公司、研究和学术界、其他）、国家（英国、德国、法国、西班牙、意大利、荷兰、瑞士、俄罗斯、比利时、土耳其和欧洲其他地区）行业趋势和预测到 2028 年
市场分析与洞察：欧洲内容许可市场的电子临床结果评估 (eCOA)
内容许可市场的电子临床结果评估 (eCOA) 预计将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2021 年至 2028 年的预测期内，该市场以 14.4% 的复合年增长率增长，预计到 2028 年将达到 322,161.98 万美元。采用 eCOA 的动力在于制药行业希望与患者进行更密切的接触，这是内容许可市场电子临床结果评估 (eCOA) 的主要驱动因素。
电子临床结果评估 (eCOA) 是在临床试验中以电子方式捕获数据的方法。它可以大幅提高研究数据的质量，同时满足监管要求。eCOA 采用手持设备、平板电脑或网络等技术，让试验参与者、医生和护理人员直接报告与医疗结果相关的信息。
由于能够收集大量数据同时确保高质量，对电子临床结果评估 (eCOA) 的需求不断增长，这加速了内容授权市场的电子临床结果评估 (eCOA) 的发展。实施和使用这些系统相关的高额初始财务成本可能会限制内容授权市场的电子临床结果评估 (eCOA)。创新和技术进步水平的提高（AI、ML、精准试验、精准引导干预、IoMT）为内容授权市场的电子临床结果评估 (eCOA) 创造了机会。缺乏训练有素的专业人员进行准确的数据解释是内容授权市场的电子临床结果评估 (eCOA) 面临的主要挑战。
这份内容授权市场电子临床结果评估 (eCOA) 报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解内容授权市场情景的分析和电子临床结果评估 (eCOA)，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案以实现您的预期目标。
内容许可市场范围和市场规模的电子临床结果评估 (eCOA)
内容授权市场的电子临床结果评估 (eCOA) 按照产品、方法、最终用户和平台进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
- 根据产品，内容许可市场的电子临床结果评估 (eCOA) 分为本地解决方案、基于云的解决方案和基于 Web 的解决方案。2021 年，本地部分在内容许可市场的电子临床结果评估 (eCOA) 中占有最大的市场份额，因为本地是永久许可证，可为客户提供一组固定的研究。
- 根据方法，内容许可市场的电子临床结果评估 (eCOA) 分为临床报告结果评估 (ClinRO)、患者报告结果评估 (PRO)、观察者报告结果评估 (ObsRO) 和绩效结果评估 (PerfO)。2021 年，临床报告结果评估 (ClinRO) 部分在内容许可市场的电子临床结果评估 (eCOA) 中占有最大市场份额，因为 ClinRO 测量涉及对被认为与疾病或状况相关的可观察体征、行为或其他身体表现的临床判断或解释。
- 根据最终用户，内容许可的电子临床结果评估 (eCOA) 市场细分为商业服务提供商、医院和移植中心以及研究实验室和学术机构。2021 年，研究实验室和学术机构细分市场在内容许可的电子临床结果评估 (eCOA) 市场中占有最大市场份额，因为临床和药物开发行业广泛使用的研究组织和学术机构主要指在临床试验中执行一项或多项功能的学术和/或非营利机构。
- 根据平台，内容许可市场的电子临床结果评估 (eCOA) 细分为合同研究组织、制药和生物制药公司、医疗器械制造商、咨询服务公司、医院和临床实验室、研究和学术界等。2021 年，合同研究组织部门在内容许可市场的电子临床结果评估 (eCOA) 中占有最大的市场份额，因为合同研究组织 (CRO) 是一种以外包药物研究服务（针对药品和医疗器械）的形式为制药和生物技术行业提供支持的服务组织。
欧洲电子临床结果评估 (eCOA) 内容许可市场国家级分析
对欧洲内容许可市场的电子临床结果评估 (eCOA) 进行了分析，并按国家、产品、方法、最终用户和平台提供了市场规模信息。
欧洲内容许可市场电子临床结果评估 (eCOA) 报告涵盖的国家包括英国、德国、法国、西班牙、意大利、荷兰、瑞士、俄罗斯、比利时、土耳其和欧洲其他地区。
英国占据了最大的市场份额，因为该地区制药行业在研发方面的支出很高，疾病的发病率不断上升，对高效的药物研究和试验的需求也随之增加，因此电子临床结果评估 (eCOA) 在该国占据主导地位。德国占据第二大市场份额，因为与该地区的其他国家相比，德国进行的临床试验数量非常多，这推动了该地区的市场发展。
报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了欧洲品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。
临床试验数量不断增加
内容授权市场电子临床结果评估 (eCOA) 还为您提供每个国家/地区行业增长的详细市场分析，包括销售额、组件销售额、技术发展对内容授权市场电子临床结果评估 (eCOA) 的影响以及监管情景的变化及其对内容授权市场电子临床结果评估 (eCOA) 的支持。数据涵盖 2011 年至 2019 年的历史时期。
内容许可市场份额分析的竞争格局和电子临床结果评估 (eCOA)
内容授权市场竞争格局的电子临床结果评估 (eCOA) 提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、欧洲业务、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对欧洲内容授权市场电子临床结果评估 (eCOA) 的关注有关。
欧洲内容许可市场电子临床结果评估 (eCOA) 报告中涵盖的主要参与者包括 Oracle、IBM Corporation、Dassault Systemes、Parexel International Corporation、ERT Clinical、ArisGlobal、Kayentis、Anju Software, Inc.、Signant Health、YPrime LLC 和 Bioclinica 等国内参与者。DBMR 分析师了解竞争优势，并为每个竞争对手分别提供竞争分析。
全球各地的公司也发起了许多产品开发，这也加速了内容授权市场的电子临床结果评估（eCOA）的增长。
例如，
- 2021 年 2 月，领先的临床终点数据收集全球数据和技术公司 ERT Clinical 推出了一款功能强大的新解决方案 eCOA Multimedia，用于在临床试验 eCOA 评估中收集、处理和分析照片和音频。通过此次新产品发布，该公司扩大了其产品线。
合作、合资和其他战略通过扩大覆盖范围和存在感来提高公司的市场份额。它还有利于组织通过扩大规模范围来改进其针对授权内容的电子临床结果评估 (eCOA) 产品。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 EUROPE PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE OF ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) IN THE AGE OF PATIENT CENTRICITY
5.1.2 GROWING DEMAND FOR ECOA DUE TO ITS CAPABILITY TO COLLECT LARGE AMOUNTS OF DATA WHILE SIMULTANEOUSLY ENSURING HIGH QUALITY
5.1.3 EMERGING TECHNOLOGICAL TRENDS BY PROVIDING A GREATER UNDERSTANDING OF EDC AND ECOA/EPRO PENETRATION IN PHARMACEUTICAL MARKETS
5.1.4 GROWING ACCEPTANCE OF ECOA TO ENGAGE MORE CLOSELY WITH PATIENTS BY PHARMA INDUSTRY
5.1.5 RISING NEED TOWARDS ELECTRONIC DATA CAPTURING FOR EFFICIENCY OF CLINICAL TRIALS
5.1.6 COST-EFFICIENCY AND RELIABILITY PROVIDED BY THE ECOA
5.1.7 RISING NUMBER OF CLINICAL TRIALS REGULATED BY FDA AND APPROVED BY INSTITUTIONAL REVIEW BOARD (IRB) FOR PATIENT SAFETY IN MULTI-CENTER TRIALS
5.2 RESTRAINTS
5.2.1 HIGH INITIAL COSTS ASSOCIATED WITH THE IMPLEMENTATION AND UTILIZATION OF THE SYSTEMS
5.2.2 LACK OF AWARENESS ABOUT REGULATIONS RELATED TO THE DATA MANAGEMENT
5.3 OPPORTUNITIES
5.3.1 RISING LEVELS OF INNOVATIONS AND ADVANCED TECHNOLOGIES
5.3.2 INCREASING PARTNERSHIPS AND COLLABORATIONS FOR CLINICAL RESEARCHES
5.3.3 DIGITIZATION OF CLINICAL TRIALS AIMS AT PERFORMING THEIR END-TO-END DIGITAL TRANSFORMATION
5.3.4 INCREASING COLLABORATION BETWEEN INDUSTRY AND GOVERNMENT FOR CLINICAL TRIALS UNDER GOVERNMENT POLICIES
5.4 CHALLENGES
5.4.1 LACK OF WELL-TRAINED PROFESSIONALS FOR ACCURATE DATA INTERPRETATION
5.4.2 LACK OF PROPER IT INFRASTRUCTURE IN MANY DEVELOPING COUNTRIES
6 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 ON-PREMISE SOLUTIONS
6.3 CLOUD BASED SOLUTIONS
6.4 WEB BASED SOLUTIONS
7 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH
7.1 OVERVIEW
7.2 CLINICIAN REPORTED OUTCOME ASSESSMENT (CLINRO)
7.3 PATIENT REPORTED OUTCOME ASSESSMENT (PRO)
7.4 OBSERVER REPORTED OUTCOME ASSESSMENT (OBSRO)
7.5 PERFORMANCE OUTCOME ASSESSMENT (PERFO)
8 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER
8.1 OVERVIEW
8.2 RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS
8.3 HOSPITALS AND TRANSPLANT CENTERS
8.4 COMMERCIAL SERVICE PROVIDERS
9 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM
9.1 OVERVIEW
9.2 CONTRACT RESEARCH ORGANIZATIONS
9.3 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
9.4 MEDICAL DEVICE MANUFACTURERS
9.5 HOSPITALS AND CLINICAL LABORATORIES
9.6 CONSULTING SERVICE COMPANIES
9.7 RESEARCH AND ACADEMIA
9.8 OTHERS
10 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET, BY REGION
10.1 EUROPE
10.1.1 U.K.
10.1.2 GERMANY
10.1.3 SPAIN
10.1.4 FRANCE
10.1.5 ITALY
10.1.6 SWITZERLAND
10.1.7 NETHERLANDS
10.1.8 BELGIUM
10.1.9 TURKEY
10.1.10 RUSSIA
10.1.11 REST OF EUROPE
11 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET: COMPANY LANDSCAP
11.1 COMPANY SHARE ANALYSIS: EUROPE
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 ORACLE
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 PAREXEL INTERNATIONAL CORPORATION
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENTS
13.3 ERT CLINICAL
13.3.1 COMPANY SNAPSHOT
13.3.2 COMPANY SHARE ANALYSIS
13.3.3 PRODUCT PORTFOLIO
13.3.4 RECENT DEVELOPMENTS
13.4 DASSAULT SYSTÈMES
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 PRODUCT PORTFOLIO
13.4.5 RECENT DEVELOPMENTS
13.5 BIOCLINICA
13.5.1 COMPANY SNAPSHOT
13.5.2 COMPANY SHARE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENTS
13.6 IBM CORPORATION
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 CLINICAL INK
13.7.1 COMPANY SNAPSHOT
13.7.2 PRODUCT PORTFOLIO
13.7.3 RECENT DEVELOPMENTS
13.8 KAYENTIS
13.8.1 COMPANY SNAPSHOT
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENTS
13.9 ANJU SOFTWARE, INC.
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENTS
13.1 ARISEUROPE
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENTS
13.11 ECLINICAL SOLUTIONS LLC
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENTS
13.12 SIGNANT HEALTH
13.12.1 COMPANY SNAPSHOT
13.12.2 SOLUTION PORTFOLIO
13.12.3 RECENT DEVELOPMENTS
13.13 WIRB-COPERNICUS GROUP
13.13.1 COMPANY SNAPSHOT
13.13.2 SERVICE PORTFOLIO
13.13.3 RECENT DEVELOPMENTS
13.14 YPRIME LLC
13.14.1 COMPANY SNAPSHOT
13.14.2 PRODUCT PORTFOLIO
13.14.3 RECENT DEVELOPMENTS
14 QUESTIONNAIRE
15 RELATED REPORTS
表格列表
LIST OF TABLES
TABLE 1 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 2 EUROPE ON-PREMISE SOLUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 3 EUROPE CLOUD BASED SOLUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 4 EUROPE WEB BASED SOLUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 5 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 6 EUROPE CLINICIAN REPORTED OUTCOME ASSESSMENT (CLINRO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 7 EUROPE PATIENT REPORTED OUTCOME ASSESSMENT (PRO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 8 EUROPE OBSERVER REPORTED OUTCOME ASSESSMENT (OBSRO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 9 EUROPE PERFORMANCE OUTCOME ASSESSMENT (PERFO) IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 10 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 11 EUROPE RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 12 EUROPE HOSPITALS AND TRANSPLANT CENTERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 13 EUROPE COMMERCIAL SERVICE PROVIDERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 14 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 15 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 16 EUROPE PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 17 EUROPE MEDICAL DEVICE MANUFACTURERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 18 EUROPE HOSPITALS AND CLINICAL LABORATORIES IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 19 EUROPE CONSULTING SERVICE COMPANIES IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 20 EUROPE RESEARCH AND ACADEMIA IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 21 EUROPE OTHERS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 22 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND)
TABLE 23 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 24 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 25 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 26 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 27 U.K. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 28 U.K. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 29 U.K. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 30 U.K. ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 31 GERMANY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 32 GERMANY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 33 GERMANY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 34 GERMANY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 35 SPAIN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 36 SPAIN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 37 SPAIN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 38 SPAIN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 39 FRANCE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 40 FRANCE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 41 FRANCE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 42 FRANCE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 43 ITALY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 44 ITALY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 45 ITALY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 46 ITALY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 47 SWITZERLAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 48 SWITZERLAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 49 SWITZERLAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 50 SWITZERLAND ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 51 NETHERLANDS ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 52 NETHERLANDS ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 53 NETHERLANDS ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 54 NETHERLANDS ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 55 BELGIUM ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 56 BELGIUM ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 57 BELGIUM ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 58 BELGIUM ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 59 TURKEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 60 TURKEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 61 TURKEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 62 TURKEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 63 RUSSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
TABLE 64 RUSSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY APPROACH, 2019-2028 (USD THOUSAND)
TABLE 65 RUSSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 66 RUSSIA ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PLATFORM, 2019-2028 (USD THOUSAND)
TABLE 67 REST OF EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET, BY PRODUCT, 2019-2028 (USD THOUSAND)
图片列表
LIST OF FIGURES
FIGURE 1 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SEGMENTATION
FIGURE 2 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: DROC ANALYSIS
FIGURE 4 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SEGMENTATION
FIGURE 10 GROWING ACCEPTANCE OF ECOA TO ENGAGE MORE CLOSELY WITH PATIENTS BY PHARMA INDUSTRY IS EXPECTED TO DRIVE EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 ON-PREMISE SOLUTIONS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET IN 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET
FIGURE 13 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT, 2020
FIGURE 14 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY APPROACH, 2020
FIGURE 15 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY END USER, 2020
FIGURE 16 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PLATFORM, 2020
FIGURE 17 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: SNAPSHOT (2020)
FIGURE 18 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020)
FIGURE 19 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2021 & 2028)
FIGURE 20 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY GEOGRAPHY (2020 & 2028)
FIGURE 21 EUROPE ELECTRONIC OUTCOME ASSESSMENT (ECOA) FOR CONTENT LICENSED MARKET: BY PRODUCT (2021-2028)
FIGURE 22 EUROPE ELECTRONIC CLINICAL OUTCOME ASSESSMENT FOR CONTENT LICENSED MARKET: COMPANY SHARE 2020(%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
